BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pathology News - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pathologynews.com
X-WR-CALDESC:Events for Pathology News
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20261025T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20250916T130000
DTEND;TZID=Europe/London:20250916T140000
DTSTAMP:20260829T202439
CREATED:20250827T133756Z
LAST-MODIFIED:20250827T152729Z
UID:100115251-1758027600-1758031200@www.pathologynews.com
SUMMARY:Can AI Predict Patient Outcomes in Ovarian Cancer?
DESCRIPTION:0000Days00Hrs00Min00SecExperimental image-based AI models are very good at extracting new information from standard H&E pathology slides. However\, the biological interpretation of these novel findings is a challenge. In this webinar\, Dr. Anna Laury\, Clinical Researcher at the University of Helsinki\, will explain how they used scanned H&E slides of high-grade serous carcinoma of the tube/ovary (HGSC) together with spatially resolved transcriptomics to explore whether AI findings actually represent biological differences in these tumors. \nHigh-grade serous carcinoma of the tube/ovary (HGSC) is characterized by aggressive behavior\, chemotherapy resistance\, and low 5-year survival\, but also exhibits striking variability in outcome. Our understanding of this disease is limited\, partly due to considerable tumor heterogeneity\, and predicting any individual patient’s response to therapy is challenging. \nDr. Laury’s team used Aiforia® Create to train an AI model to predict patient outcome in HGSC by identifying tumor regions that are highly associated with outcome status. The tumor regions identified by the AI model are currently indistinguishable by pathologists. They then used spatially resolved transcriptomics to profile these AI-identified tumor regions and identify molecular features related to disease outcome. \nRegister for the webinar to hear more about this proof-of-concept study\, which shows that AI-guided spatial transcriptomic analysis improves recognition of biologic features relevant to patient outcomes. \nRegister NowSpeakersAnna Laury\, MD\, PhD\nClinical Researcher\nUniversity of Helsinki \nDr. Laury is a clinical researcher at the University of Helsinki. She received her medical degree from the University of California\, Los Angeles and pathology training at Brigham & Women’s Hospital. Her clinical interests include women’s and perinatal pathology\, and her research is currently focused on the development and progression of tubo-ovarian serous carcinoma. \nDarshan Kumar\, PhD\nDirector of the Global FAS team\nAiforia Technologies \nDarshan Kumar has worked at Aiforia for over four years as a Customer Success Manager and Scientist. He currently leads the global team of Field Application Scientists. He did his PhD research in cell and molecular biology at the University of Helsinki and has a master’s in Biomedical Sciences from Leiden University.
URL:https://www.pathologynews.com/event/can-ai-predict-patient-outcomes-in-ovarian-cancer/
LOCATION:Online
CATEGORIES:Live Online Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.pathologynews.com/wp-content/uploads/2025/08/Can-AI-Predict-Patient-Outcomes-in-Ovarian-Cancer.jpg
END:VEVENT
END:VCALENDAR